Lakeshore Biopharma Co Stock Market Value
| LSBCF Stock | 0.06 0.02 19.50% |
| Symbol | LakeShore |
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
LakeShore Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LakeShore Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LakeShore Biopharma.
| 12/01/2025 |
| 03/01/2026 |
If you would invest 0.00 in LakeShore Biopharma on December 1, 2025 and sell it all today you would earn a total of 0.00 from holding LakeShore Biopharma Co or generate 0.0% return on investment in LakeShore Biopharma over 90 days. LakeShore Biopharma is related to or competes with Adagene, Alto Neuroscience, Aspire BioPharma, Biostem Technologies, Can Fite, Cognition Therapeutics, and Mirum Pharmaceuticals. LakeShore Biopharma is entity of United States More
LakeShore Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LakeShore Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LakeShore Biopharma Co upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.29) | |||
| Maximum Drawdown | 55.38 | |||
| Value At Risk | (35.00) | |||
| Potential Upside | 1.19 |
LakeShore Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LakeShore Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LakeShore Biopharma's standard deviation. In reality, there are many statistical measures that can use LakeShore Biopharma historical prices to predict the future LakeShore Biopharma's volatility.| Risk Adjusted Performance | (0.21) | |||
| Jensen Alpha | (3.15) | |||
| Total Risk Alpha | (4.16) | |||
| Treynor Ratio | (2.11) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of LakeShore Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
LakeShore Biopharma March 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.21) | |||
| Market Risk Adjusted Performance | (2.10) | |||
| Mean Deviation | 5.95 | |||
| Coefficient Of Variation | (353.68) | |||
| Standard Deviation | 10.71 | |||
| Variance | 114.65 | |||
| Information Ratio | (0.29) | |||
| Jensen Alpha | (3.15) | |||
| Total Risk Alpha | (4.16) | |||
| Treynor Ratio | (2.11) | |||
| Maximum Drawdown | 55.38 | |||
| Value At Risk | (35.00) | |||
| Potential Upside | 1.19 | |||
| Skewness | (3.02) | |||
| Kurtosis | 9.97 |
LakeShore Biopharma Backtested Returns
LakeShore Biopharma has Sharpe Ratio of -0.29, which conveys that the firm had a -0.29 % return per unit of risk over the last 3 months. LakeShore Biopharma exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify LakeShore Biopharma's Mean Deviation of 5.95, standard deviation of 10.71, and Risk Adjusted Performance of (0.21) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.44, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, LakeShore Biopharma will likely underperform. At this point, LakeShore Biopharma has a negative expected return of -3.24%. Please make sure to verify LakeShore Biopharma's total risk alpha and the relationship between the skewness and period momentum indicator , to decide if LakeShore Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.47 |
Modest reverse predictability
LakeShore Biopharma Co has modest reverse predictability. Overlapping area represents the amount of predictability between LakeShore Biopharma time series from 1st of December 2025 to 15th of January 2026 and 15th of January 2026 to 1st of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LakeShore Biopharma price movement. The serial correlation of -0.47 indicates that about 47.0% of current LakeShore Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.47 | |
| Spearman Rank Test | -0.5 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out LakeShore Biopharma Correlation, LakeShore Biopharma Volatility and LakeShore Biopharma Performance module to complement your research on LakeShore Biopharma. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
LakeShore Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.